A double blind clinical trial evaluating the relative pharmacokinetics and bioavailability of oral creatine monohydrate when combined with either isomaltulose or dextrose in healthy adult males
A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a Bacillus coagulans-based product on functional intestinal gas symptoms
Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing.
Autorzy:
Balke-Want H; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA. Keerthi V; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA. Gkitsas N; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA. Mancini AG; MaxCyte, Inc, Rockville, MD, USA. Kurgan GL; Integrated DNA Technologies, Inc, Coralville, IA, 52241, USA. Fowler C; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA. Xu P; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA. Liu X; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA. Asano K; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA. Patel S; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA. Fisher CJ; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA. Brown AK; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA. Tunuguntla RH; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA. Patel S; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA. Sotillo E; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA. Mackall CL; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA. . FeldmanSA; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA. .
Pokaż więcej
Źródło:
Molecular cancer [Mol Cancer] 2023 Jun 26; Vol. 22 (1), pp. 100. Date of Electronic Publication: 2023 Jun 26.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Mitral annular plane systolic excursion and tricuspid annular plane systolic excursion for risk stratification of acute pulmonary embolism.
Autorzy:
Matos JD; Departments of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.; Cardiovascular Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA. Balachandran I; Departments of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA. Heidinger BH; Departments of Radiology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Viena, Vienna, Austria. Mohebali D; Departments of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.; Cardiovascular Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA. FeldmanSA; Department of Medicine, Boston University School of Medicine, Boston Medical Center, Boston, MA, USA.; Section of Cardiovascular Medicine, Boston University School of Medicine, Boston Medical Center, Boston, MA, USA. McCormick I; Departments of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.; Cardiovascular Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA. Litmanovich D; Departments of Radiology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA. Manning WJ; Departments of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.; Cardiovascular Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.; Departments of Radiology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA. Carroll BJ; Departments of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.; Cardiovascular Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modules.
Autorzy:
Jin J; Center for Cellular Engineering, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, 10 Center Drive, MSC-1184, Building 10, Room 3C720, Bethesda, MD, 20892-1184, USA. Gkitsas N; Center for Cellular Engineering, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, 10 Center Drive, MSC-1184, Building 10, Room 3C720, Bethesda, MD, 20892-1184, USA. Fellowes VS; Center for Cellular Engineering, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, 10 Center Drive, MSC-1184, Building 10, Room 3C720, Bethesda, MD, 20892-1184, USA. Ren J; Center for Cellular Engineering, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, 10 Center Drive, MSC-1184, Building 10, Room 3C720, Bethesda, MD, 20892-1184, USA. FeldmanSA; Surgery Branch, National Cancer Institute, NIH, Bethesda, MD, USA. Hinrichs CS; Experimental Transplantation and Immunology Branch, National Cancer Institute, NIH, Bethesda, MD, USA. Stroncek DF; Center for Cellular Engineering, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, 10 Center Drive, MSC-1184, Building 10, Room 3C720, Bethesda, MD, 20892-1184, USA. Highfill SL; Center for Cellular Engineering, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, 10 Center Drive, MSC-1184, Building 10, Room 3C720, Bethesda, MD, 20892-1184, USA. .
Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.
Autorzy:
Abate-Daga D; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America. Speiser DE; Department of Oncology, Ludwig Center, University of Lausanne, Lausanne, Switzerland. Chinnasamy N; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America. Zheng Z; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America. Xu H; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America. FeldmanSA; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America. Rosenberg SA; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America. Morgan RA; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2014 Mar 28; Vol. 9 (3), pp. e93321. Date of Electronic Publication: 2014 Mar 28 (Print Publication: 2014).
Typ publikacji:
Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
